Peripheral Drug Eluting Balloons Market to Grow at 8.6% CAGR Through 2033, Forecasts Persistence Market Research

✅Global Peripheral Drug Eluting Balloons Market Overview

Peripheral drug eluting balloons (DEBs) are critical medical devices used in minimally invasive procedures to treat peripheral artery disease (PAD), particularly by addressing arterial stenosis through targeted drug delivery. The technology combines angioplasty with localized drug application, reducing restenosis and improving long-term vascular outcomes. The global peripheral drug eluting balloons market was valued at US$ 808.2 million in 2022 and is projected to grow at a robust CAGR of 8.6% to reach approximately US$ 1.9 billion by 2033. This significant growth is attributed to rising prevalence of PAD, increasing geriatric population, and growing awareness and adoption of advanced vascular interventional technologies.

Leading the charge in this market are paclitaxel-coated DEBs, which held a dominant 47.8% share in 2022 due to their proven efficacy in inhibiting neointimal hyperplasia. North America, particularly the United States, stands as the leading regional market, accounting for 36.2% of global revenue. This is driven by a high burden of PAD, advanced healthcare infrastructure, and a large aging population. Meanwhile, Asia Pacific is emerging as a fast-growing region with nations like China benefiting from favorable healthcare policies and increasing medical device access. The market's growth is supported by global trends such as lifestyle changes, higher diabetes incidence, and the demand for minimally invasive solutions in vascular surgery.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/27211

✅Key Highlights from the Peripheral Drug Eluting Balloons Market Report

➤ The market is expected to surge at an 8.6% CAGR from 2023 to 2033.
➤ Paclitaxel drug-coated balloons accounted for 47.8% market share in 2022.
➤ The United States led the global market with a 36.2% share in 2022.
➤ Peripheral arterial disease is the top indication, holding a 37.8% share.
➤ China and Germany are emerging as lucrative markets due to policy support and infrastructure.
➤ The global market reached US$ 808.2 million in 2022 and is projected to hit US$ 1.9 billion by 2033.

✅Market Segmentation Analysis

Peripheral drug eluting balloons are categorized by drug coating, indication, artery type, and end user. By drug coating, the market is primarily driven by paclitaxel-coated balloons, owing to their well-established clinical efficacy in suppressing smooth muscle proliferation. Meanwhile, sirolimus-coated DEBs are gaining interest due to their alternative antiproliferative mechanisms and promising results in ongoing clinical trials. This segment is expected to grow as newer devices receive regulatory approval and long-term data supports their use.

By indication, peripheral arterial disease (PAD) is the dominant application area, capturing 37.8% of the market in 2022. PAD remains prevalent among older adults, with risk factors like diabetes, smoking, and hypertension contributing to disease incidence. Other indications include in-stent restenosis, aneurysms, and carotid artery stenosis. From the end-user perspective, hospitals represent the largest segment, attributed to the availability of vascular surgeons and interventional radiologists, as well as access to catheterization labs. However, ambulatory surgical centers and outpatient clinics are gaining ground due to increasing preference for same-day, less invasive procedures.

✅Regional Insights

In North America, the U.S. dominates due to its advanced medical infrastructure, extensive PAD patient population, and higher adoption of new interventional technologies. In 2021, approximately 8.5 million Americans were reported to suffer from PAD, and this prevalence continues to grow due to rising obesity, diabetes, and aging. Moreover, ongoing investments in clinical research and early adoption of sirolimus-based DEBs further propel the market in this region.

Asia Pacific, particularly China, is witnessing rapid market expansion owing to increasing healthcare reforms, government reimbursement schemes, and a growing elderly population. With a 6.5% market share in 2022, China has shown considerable momentum, supported by partnerships between local and global manufacturers. Meanwhile, Germany, with a 6.3% share, remains a strong European market thanks to its well-established healthcare system, patient awareness, and swift integration of emerging technologies.

✅Market Drivers

The rising prevalence of peripheral arterial disease globally is a primary growth catalyst. Risk factors such as obesity, smoking, sedentary lifestyles, and an aging population are driving up PAD incidence. The World Health Organization anticipates that 2 billion individuals will be over 60 by 2050, significantly increasing demand for vascular interventions. Additionally, the shift toward minimally invasive procedures, coupled with improvements in drug coating technologies, is enhancing the safety, efficacy, and adoption rate of DEBs. Government health initiatives in low- and middle-income countries are also playing a vital role by expanding access to PAD treatments.

✅Market Restraints

Despite the positive outlook, several factors are limiting market growth. The high cost of peripheral drug eluting balloons remains a major barrier, especially in cost-sensitive markets or healthcare systems with limited reimbursement frameworks. Compared to conventional angioplasty, DEBs carry a premium due to advanced drug coatings and stringent manufacturing standards. Additionally, there is limited availability of long-term clinical data proving DEBs' superiority over stents or standard balloons. Many healthcare providers remain cautious about adopting these devices without large-scale randomized trials that can firmly establish their benefits in different patient populations.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/27211

✅Market Opportunities

Emerging markets offer untapped potential for growth. As healthcare infrastructure improves across Asia, Latin America, and Africa, manufacturers can gain a foothold by partnering with local players and customizing products for affordability. Additionally, the development of next-generation DEBs, such as those using sirolimus and other non-paclitaxel drugs, opens new therapeutic possibilities and addresses safety concerns. Growing investment in research and development, including trials for specific subgroups (e.g., diabetic patients), could enhance product differentiation and accelerate regulatory approvals. Also, expanding applications beyond PAD to include in-stent restenosis and aneurysms may broaden the commercial scope for DEBs.

✅Frequently Asked Questions

➤ How Big is the Peripheral Drug Eluting Balloons Market?
➤ What is the Projected Growth Rate of the Market through 2033?
➤ Who are the Key Players in the Global Peripheral Drug Eluting Balloons Market?
➤ What is the Market Forecast for Peripheral Drug Eluting Balloons by 2032?
➤ Which Region is Estimated to Dominate the Industry through the Forecast Period?

✅Company Insights - Key Market Players

✦ Abbott Laboratories
✦ Boston Scientific Corporation
✦ Cook Medical Inc.
✦ MicroPort Scientific Corporation (EndovastecTM)
✦ Medtronic Plc.
✦ Cardinal Health, Inc.
✦ B. Braun Melsungen AG
✦ BIOTRONIK SE & Co. KG
✦ Becton, Dickinson and Company
✦ W. L. Gore & Associates Inc.
✦ Getinge AB
✦ Terumo Corp
✦ Kyoto Medical Planning Co Ltd
✦ iVascular S.L.U
✦ AMG International GmbH
✦ ENDOCOR GmbH
✦ Meril Life Sciences Pvt. Ltd.
✦ Nano Therapeutics Pvt Ltd
✦ Koninklijke Philips N.V.
✦ REVA Medical

✅Recent Market Developments

■ In August 2022, BD initiated a first-in-human clinical trial to assess the safety of its sirolimus-coated balloon for femoropopliteal arterial disease.
■ In June 2018, Terumo Corporation secured CE approval for its Kanshas drug-coated balloon catheter designed for treating lower extremity PAD.

✅Reasons to Buy the Peripheral Drug Eluting Balloons Market Report

Comprehensive analysis of market dynamics including drivers, restraints, and future opportunities.

In-depth segmentation of the market by drug coating, indication, artery type, and end user.

Detailed regional insights highlighting growth prospects in key markets like the U.S., China, and Germany.

Competitive landscape featuring profiles of leading global and local players.

Recent product developments and clinical advancements shaping the future of the market.

Clear projection of market size and CAGR through 2033 with actionable insights for stakeholders.

Identification of emerging trends and potential investment hotspots in low- and middle-income countries.

Tailored recommendations and strategic initiatives for market entry and expansion.

This report offers a holistic view of the Peripheral Drug Eluting Balloons Market, helping stakeholders understand both the macroeconomic forces and granular developments shaping this rapidly growing industry. With consistent innovation, growing disease burden, and expanding global access, the DEB market is well-positioned for robust growth through 2033.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.